Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies

Clinical Reviews in Allergy and Immunology

Volumn 37, Issue 2, 2009, Pages 67-79

  Lavigne Lissalde, Géraldine ^a,b,c   Rothschild, Chantal ^d   Pouplard, Claire ^e   Lapalud, Priscilla ^a   Gruel, Yves ^e   Schved, Jean François ^b   Granier, Claude ^a  

^a CNRS   (France)

^b HÔPITAL SAINT ELOI   (France)

^c DEPARTMENT OF NEUROLOGY   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e SERVICE DE DERMATOLOGIE   (France)

Author keywords

Epitope mapping; FVIII; Hemophilia A; Inhibitors

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR;

ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HEMOPHILIA A; HUMAN; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PHAGE DISPLAY; REVIEW; STEREOSPECIFICITY;

ANIMALS; AUTOANTIBODIES; BLOOD COAGULATION FACTOR INHIBITORS; EPITOPE MAPPING; FACTOR VIII; HEMOPHILIA A; HUMANS; MICE;

EID: 70349264566     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12016-009-8119-0     Document Type: Review

References (78)

1. G Lavigne-Lissalde JF Schved C Granier, et al. 2005 Anti-factor VIII antibodies: a 2005 update Thromb Haemost 94 4 760 769 16270627
2. S Ehrenforth W Kreuz I Scharrer, et al. 1992 Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs Lancet 339 8793 594 598 1347102 10.1016/0140-6736(92)90874-3 1:STN:280:DyaK387mslOhsg%3D%3D
3. M Franchini D Veneri 2005 Acquired coagulation inhibitor-associated bleeding disorders: an update Hematology 10 6 443 449 16321808 10.1080/10245330500276642 1:CAS:528:DC%2BD2MXht1Kntb%2FN (Pubitemid 43123466)
4. B Wootla S Dasgupta JD Dimitrov, et al. 2008 Hydrolysis of coagulation factors by circulating IgG is associated with a reduced risk for chronic allograft nephropathy in renal transplanted patients J Immunol 180 11 7714 7720 18490775 1:CAS:528:DC%2BD1cXmtVamsLs%3D
5. P Lollar CG Parker 1989 Subunit structure of thrombin-activated porcine factor VIII Biochemistry 28 2 666 674 2496750 10.1021/bi00428a038 1:CAS:528:DyaL1MXltlKksA%3D%3D (Pubitemid 19047106)
6. PJ Fay PJ Haidaris TM Smudzin 1991 Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit J Biol Chem 266 14 8957 8962 1902833 1:CAS:528:DyaK3MXksVCqt7o%3D
7. R Prescott H Nakai EL Saenko, et al. 1997 The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups Blood 89 10 3663 3671 9160671 1:CAS:528:DyaK2sXjt12ltbw%3D
8. GC White 2008 Prediction of inhibitors in hemophilia J Thrombosis Haemostasis 6 12 2045 2047 10.1111/j.1538-7836.2008.03205.x 1:CAS:528: DC%2BD1MXhtFSkurw%3D
9. Goudemand J, Laurian Y, Calvez T (2006) Curr Opin Hematol Risk of inhibitors in haemophilia and the type of factor replacement. 13(5):316-322
10. J Goudemand C Rothschild V Demiguel, et al. 2006 Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A Blood 107 1 46 51 16166584 10.1182/blood-2005-04-1371 1:CAS:528:DC%2BD28XhsVGhuw%3D%3D (Pubitemid 43054971)
11. SC Gouw JG van der Bom H Marijke van den Berg 2007 Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study Blood 109 11 4648 4654 17289808 10.1182/blood-2006-11-056291 1:CAS:528:DC%2BD2sXmt1OgtL8%3D (Pubitemid 46827754)
12. DM DiMichele BL Kroner 1999 Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: current practice implications. ISTH Factor VIII/IX Subcommittee Members Vox Sang 77 Suppl 1 31 32 10529684 10.1159/000056712 1:CAS:528:DyaK1MXmslOmur4%3D (Pubitemid 29469253)
13. JG Gilles J Arnout J Vermylen, et al. 1993 Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction Blood 82 8 2452 2461 7691260 1:CAS:528:DyaK2cXms1aq
14. M Algiman G Dietrich UE Nydegger, et al. 1992 Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals Proc Natl Acad Sci U S A 89 9 3795 3799 1570298 10.1073/pnas.89.9.3795 1:CAS:528:DyaK38XktVGktrg%3D
15. CA Fulcher S de Graaf Mahoney TS Zimmerman 1987 FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblottin Blood 69 5 1475 1480 2436689 1:CAS:528:DyaL2sXktVGntb4%3D
16. SS Shapiro 1967 The immunologic character of acquired inhibitors of antihemophilic globulin (factor 8) and the kinetics of their interaction with factor 8 J Clin Invest 46 2 147 156 6018754 1:CAS:528:DyaF2sXksFSltQ%3D%3D
17. RC Aalberse R van der Gaag J van Leeuwen 1983 Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response J Immunol 130 2 722 726 6600252 1:STN:280:DyaL3s%2Fotl2ksg%3D%3D
18. MG Jacquemin BG Desqueper A Benhida, et al. 1998 Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor Blood 92 2 496 506 9657749 1:CAS:528:DyaK1cXksFaru7k%3D
19. M Jacquemin A Benhida K Peerlinck, et al. 2000 A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor Blood 95 1 156 163 10607698 1:CAS:528: DC%2BD3cXhslKhsg%3D%3D
20. CM Kessler 2000 Acquired factor VIII autoantibody inhibitors: current concepts and potential therapeutic strategies for the future Haematologica 85 10 Suppl 57 61 11187873 1:CAS:528:DC%2BD3cXptVegsLc%3D discussion 61-53
21. JF Healey ET Parker RT Barrow, et al. 2007 The humoral response to human factor VIII in hemophilia A mice J Thromb Haemost 5 3 512 519 17181826 10.1111/j.1538-7836.2007.02373.x 1:CAS:528:DC%2BD2sXktFCju7k%3D (Pubitemid 46680684)
22. PM van Helden HM van den Berg SC Gouw, et al. 2008 IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A Br J Haematol 142 4 644 652 18510679 10.1111/j.1365-2141.2008. 07232.x (Pubitemid 352020215)
23. MS Gawryl LW Hoyer 1982 Inactivation of factor VIII coagulant activity by two different types of human antibodies Blood 60 5 1103 1109 6181833 1:CAS:528:DyaL3sXhsFagsA%3D%3D
24. K Peerlinck MG Jacquemin J Arnout, et al. 1999 Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A Blood 93 7 2267 2273 10090936 1:CAS:528:DyaK1MXit1Khtrs%3D
25. D Scandella M Mattingly R Prescott 1993 A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2 Blood 82 6 1767 1775 7691236 1:CAS:528:DyaK3sXms1yrsr8%3D
26. D Scandella GE Gilbert M Shima, et al. 1995 Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site Blood 86 5 1811 1819 7544643 1:CAS:528:DyaK2MXnslKrur8%3D
27. D Scandella 1996 Human anti-factor VIII antibodies: epitope localization and inhibitory function Vox Sang 70 Suppl 1 9 14 8869462 10.1111/j.1423-0410. 1996.tb01342.x 1:CAS:528:DyaK28XitVGlsb0%3D
28. D Scandella W Mondorf J Klinge 1998 The natural history of the immune response to exogenous factor VIII in severe haemophilia A Haemophilia 4 4 546 551 9873792 10.1046/j.1365-2516.1998.440546.x 1:STN:280:DyaK1M%2FptVCkug%3D%3D
29. C Tiarks L Pechet J Anderson, et al. 1992 Characterization of a factor VIII immunogenic site using factor VIII synthetic peptide 1687-1695 and rabbit anti-peptide antibodies Thromb Res 65 3 301 310 1378653 10.1016/0049-3848(92) 90161-3 1:CAS:528:DyaK38XitFamtrg%3D
30. D Scandella 1999 Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies Vox Sang 77 Suppl 1 17 20 10529680 10.1159/000056708 1:CAS:528:DyaK1MXmslOmtbg%3D
31. PJ Fay K Koshibu M Mastri 1999 The A1 and A2 subunits of factor VIIIa synergistically stimulate factor IXa catalytic activity J Biol Chem 274 22 15401 15406 10336428 10.1074/jbc.274.22.15401 1:CAS:528:DyaK1MXjsV2gsrc%3D (Pubitemid 29254903)
32. JF Healey IM Lubin H Nakai, et al. 1995 Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII J Biol Chem 270 24 14505 14509 7540171 10.1074/jbc.270.24.14505 1:CAS:528:DyaK2MXmsVSitL4%3D
33. C Ansong SM Miles PJ Fay 2006 Epitope mapping factor VIII A2 domain by affinity-directed mass spectrometry: residues 497-510 and 584-593 comprise a discontinuous epitope for the monoclonal antibody R8B12 J Thromb Haemost 4 4 842 847 16634755 10.1111/j.1538-7836.2006.01831.x 1:CAS:528:DC%2BD28XjvFerurk%3D
34. EL Saenko M Shima KJ Rajalakshmi, et al. 1994 A role for the C2 domain of factor VIII in binding to von Willebrand factor J Biol Chem 269 15 11601 11605 7512568 1:CAS:528:DyaK2cXivFCqtb4%3D
35. PA Foster CA Fulcher RA Houghten, et al. 1990 Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine Blood 75 10 1999 2004 2110840 1:CAS:528:DyaK3cXktlyis7k%3D
36. PC Spiegel Jr. M Jacquemin JM Saint-Remy, et al. 2001 Structure of a factor VIII C2 domain-immunoglobulin G4 kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII Blood 98 1 13 19 11418455 10.1182/blood.V98.1.13 1:CAS:528:DC%2BD3MXkvFSmur4%3D
37. K Nogami M Shima H Nakai, et al. 1999 Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect Br J Haematol 107 1 196 203 10520041 10.1046/j.1365-2141.1999.01673.x 1:CAS:528:DyaK1MXnsVehsLo%3D (Pubitemid 29500826)
38. K Nogami M Shima JC Giddings, et al. 2007 Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain Int J Hematol 85 4 317 322 17483075 10.1532/IJH97.06192 1:CAS:528:DC%2BD2sXntFOku7Y%3D (Pubitemid 47182058)
39. S Villard D Piquer S Raut, et al. 2002 Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8 J Biol Chem 277 30 27232 27239 12011059 10.1074/jbc.M203415200 1:CAS:528:DC%2BD38XlvV2itb4%3D (Pubitemid 34951740)
40. EL Saenko M Shima GE Gilbert, et al. 1996 Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition J Biol Chem 271 44 27424 27431 8910322 10.1074/jbc.271.44.27424 1:CAS:528:DyaK28XmvVWmt78%3D (Pubitemid 26367300)
41. EL Saenko D Scandella 1997 The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor J Biol Chem 272 29 18007 18014 9218428 10.1074/jbc.272.29. 18007 1:CAS:528:DyaK2sXkslKntL8%3D (Pubitemid 27306379)
42. EL Saenko D Scandella AV Yakhyaev, et al. 1998 Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets J Biol Chem 273 43 27918 27926 9774404 10.1074/jbc.273.43.27918 1:CAS:528:DyaK1cXntVCmtLo%3D (Pubitemid 28496081)
43. SL Meeks JF Healey ET Parker, et al. 2008 Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors Blood 112 4 1151 1153 18495957 10.1182/blood-2008-01-132639 1:CAS:528:DC%2BD1cXpvVOktrw%3D
44. K Fijnvandraat PH Celie EA Turenhout, et al. 1998 A human alloantibody interferes with binding of factor IXa to the factor VIII light chain Blood 91 7 2347 2352 9516133 1:CAS:528:DyaK1cXitF2hs74%3D
45. PJ Lenting JW van de Loo MJ Donath, et al. 1996 The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX J Biol Chem 271 4 1935 1940 8567641 10.1074/jbc.271.4. 1935 1:CAS:528:DyaK28XnsF2lsw%3D%3D
46. D Zhong EL Saenko M Shima, et al. 1998 Some human inhibitor antibodies interfere with factor VIII binding to factor IX Blood 92 1 136 142 9639509 1:CAS:528:DyaK1cXktleru78%3D
47. D Eaton H Rodriguez GA Vehar 1986 Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity Biochemistry 25 2 505 512 3082357 10.1021/bi00350a035 1:CAS:528: DyaL28Xos1Sjsw%3D%3D
48. DD Pittman M Millenson K Marquette, et al. 1992 A2 domain of human recombinant-derived factor VIII is required for procoagulant activity but not for thrombin cleavage Blood 79 2 389 397 1730084 1:CAS:528:DyaK38XhsVyqt7k%3D
49. CR Hay CA Ludlam BT Colvin, et al. 1998 Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation Thromb Haemost 79 4 762 766 9569189 1:CAS:528:DyaK1cXit12nsL8%3D
50. JG Gilles R Lavend'homme K Peerlinck, et al. 1999 Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes Thromb Haemost 82 1 40 45 10456452 1:CAS:528: DyaK1MXkvF2ls7g%3D
51. GE Gilbert AA Arena 1996 Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-L-serine J Biol Chem 271 19 11120 11125 8626656 10.1074/jbc.271.19.11120 1:CAS:528:DyaK28XivV2ju7Y%3D (Pubitemid 26155940)
52. TC Hsu KP Pratt AR Thompson 2008 The factor VIII C1 domain contributes to platelet binding Blood 111 1 200 208 17916745 10.1182/blood-2007-01-068957 1:CAS:528:DC%2BD1cXjtVKisg%3D%3D
53. JG Gilles MG Jacquemin JM Saint-Remy 1997 Factor VIII inhibitors Thromb Haemost 78 1 641 646 9198231 1:CAS:528:DyaK2sXktFelu7w%3D
54. G Lavigne-Lissalde S Lacroix-Desmazes B Wootla, et al. 2007 Molecular characterization of human B domain-specific anti-factor VIII monoclonal antibodies generated in transgenic mice Thromb Haemost 98 1 138 147 17598006 1:CAS:528:DC%2BD2sXotVyqsbg%3D
55. A Coutinho MD Kazatchkine S Avrameas 1995 Natural autoantibodies Curr Opin Immunol 7 6 812 818 8679125 10.1016/0952-7915(95)80053-0 1:CAS:528:DyaK28XnsFKjsw%3D%3D (Pubitemid 26038522)
56. MD Kazatchkine Y Sultan EJ Burton-Kee, et al. 1980 Circulating immune complexes containing anti-VIII antibodies in multi-transfused patients with haemophilia A Clin Exp Immunol 39 2 315 320 6771074 1:STN:280: DyaL3c3itlGjtw%3D%3D
57. W Mondorf J Klinge NL Luban, et al. 2001 Low factor VIII recovery in haemophilia A patients without inhibitor titre is not due to the presence of anti-factor VIII antibodies undetectable by the Bethesda assay Haemophilia 7 1 13 19 11136375 10.1046/j.1365-2516.2001.00463.x 1:CAS:528:DC%2BD3MXnsFWgtLc%3D (Pubitemid 32162192)
58. S Lacroix-Desmazes A Moreau Sooryanarayana, et al. 1999 Catalytic activity of antibodies against factor VIII in patients with hemophilia A Nat Med 5 9 1044 1047 10470082 10.1038/12483 1:CAS:528:DyaK1MXlslGqtLY%3D (Pubitemid 29439576)
59. S Lacroix-Desmazes B Wootla S Dasgupta, et al. 2006 Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII J Immunol 177 2 1355 1363 16818797 1:CAS:528:DC%2BD28XmsVarsr0%3D
60. CA Fulcher S de Graaf Mahoney JR Roberts, et al. 1985 Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments Proc Natl Acad Sci U S A 82 22 7728 7732 2415970 10.1073/pnas.82.22.7728 1:CAS:528:DyaL28XksVGq (Pubitemid 16204422)
61. D Scandella S DeGraaf Mahoney M Mattingly, et al. 1988 Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli Proc Natl Acad Sci U S A 85 16 6152 6156 2457907 10.1073/pnas.85.16.6152 1:CAS:528:DyaL1cXls1yksrY%3D (Pubitemid 18209089)
62. P Lollar ET Parker PJ Fay 1992 Coagulant properties of hybrid human/porcine factor VIII molecules J Biol Chem 267 33 23652 23657 1429706 1:CAS:528:DyaK38XmtV2lsL8%3D
63. JF Healey RT Barrow HM Tamim, et al. 1998 Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII Blood 92 10 3701 3709 9808564 1:CAS:528:DyaK1cXnsVKltr8%3D
64. RT Barrow JF Healey D Gailani, et al. 2000 Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules Blood 95 2 564 568 10627463 1:CAS:528:DC%2BD3cXlsFGiuw%3D%3D
65. NR Shulman RJ Hirschman 1969 Acquired hemophilia Trans Assoc Am Physicians 82 388 397 4192751 1:STN:280:DyaE3c3gvVWmug%3D%3D
66. R Frank 1992 Spot-Synthesis: an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support Tetrahedron 48 9217 9232 10.1016/S0040-4020(01)85612-X 1:CAS:528:DyaK3sXhtVansbw%3D
67. S Raut S Villard S Grailly, et al. 2003 Anti-heavy-chain monoclonal antibodies directed to the acidic regions of the factor VIII molecule inhibit the binding of factor VIII to phospholipids and von Willebrand factor Thromb Haemost 90 3 385 397 12958606 1:CAS:528:DC%2BD3sXnsFKgtLg%3D
68. T Albert S Lange J Oldenburg, et al. 2003 [Characterization of factor VIII antibody epitopes from haemophilia A patients using cellulose bound FVIII peptide libraries] Hamostaseologie 23 1 13 17 12567194 1:CAS:528: DC%2BD3sXivVGru7Y%3D
69. EM Kopecky S Greinstetter I Pabinger, et al. 2006 Mapping of FVIII inhibitor epitopes using cellulose-bound synthetic peptide arrays J Immunol Methods 308 1-2 90 100 16376372 10.1016/j.jim.2005.10.016 1:CAS:528: DC%2BD28XmsFWitQ%3D%3D (Pubitemid 43107957)
70. GP Smith VA Petrenko 1997 Phage Display Chem Rev 97 2 391 410 11848876 10.1021/cr960065d 1:CAS:528:DyaK2sXhslamtb8%3D
71. S Villard S Lacroix-Desmazes T Kieber-Emmons, et al. 2003 Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor Blood 102 3 949 952 12676786 10.1182/blood-2002-06-1886 1:CAS:528:DC%2BD3sXlvFCmtrw%3D (Pubitemid 36917788)
72. C Kessel C Konigs R Linde, et al. 2008 Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab Mol Immunol 46 1 8 15 18715645 10.1016/j.molimm.2008.06.015 1:CAS:528: DC%2BD1cXhtFOisrbP
73. PG Martin K Sukhu E Chambers, et al. 1999 Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs Clin Lab Haematol 21 2 125 128 10342072 10.1046/j.1365-2257.1999. 00194.x 1:STN:280:DyaK1M3ntlKiug%3D%3D (Pubitemid 29234340)
74. S Shetty K Ghosh D Mohanty 2003 An ELISA assay for the detection of factor VIII antibodies - comparison with the conventional Bethesda assay in a large cohort of haemophilia samples Acta Haematol 109 1 18 22 12486318 10.1159/000067272 (Pubitemid 41754743)
75. F Towfighi S Gharagozlou RA Sharifian, et al. 2005 Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity Acta Haematol 114 2 84 90 16103630 10.1159/000086580 1:CAS:528:DC%2BD2MXnvFygu7o%3D (Pubitemid 41160935)
76. DM DiMichele 2006 Factor VIII pharmacokinetics: impact of low titer non-neutralizing inhibitors and use in determination of successful immune tolerance Haemophilia 12 Suppl 4 56 60 10.1111/j.1365-2516.2006.01335.x 1:CAS:528:DC%2BD2sXitFyktg%3D%3D (Pubitemid 44404840)
77. RJ Fulton RL McDade PL Smith, et al. 1997 Advanced multiplexed analysis with the FlowMetrix system Clin Chem 43 9 1749 1756 9299971 1:CAS:528: DyaK2sXmtVyiu7s%3D
78. G Lavigne-Lissalde C Tarrade P Lapalud S Chtourou JF Schved C Granier S Villard-Saussine 2008 Simultaneous detection and epitope mapping of anti-factor VIII antibodies Thromb Haemost 99 6 1090 1096 18521513 1:CAS:528: DC%2BD1cXotVyjsLs%3D